Clinical and economic burden of antimicrobial resistance

Lisa Maragakis, Eli N. Perencevich, Sara Cosgrove

Research output: Contribution to journalArticle

Abstract

Knowledge of the clinical and economic impact of antimicrobial resistance is useful to influence programs and behavior in healthcare facilities, to guide policy makers and funding agencies, to define the prognosis of individual patients and to stimulate interest in developing new antimicrobial agents and therapies. There are a variety of important issues that must be considered when designing or interpreting studies into the clinical and economic outcomes associated with antimicrobial resistance. One of the most misunderstood issues is how to measure cost appropriately. Although imperfect, existing data show that there is an association between antimicrobial resistance in Staphylococcus aureus, enterococci and Gram-negative bacilli and increases in mortality, morbidity, length of hospitalization and cost of healthcare. Patients with infections due to antimicrobial-resistant organisms have higher costs (US$6000-30,000) than do patients with infections due to antimicrobial-susceptible organisms; the difference in cost is even greater when patients infected with antimicrobial-resistant organisms are compared with patients without infection. Given limited budgets, knowledge of the clinical and economic impact of antibiotic-resistant bacterial infections, coupled with the benefits of specific interventions targeted to reduce these infections, will allow for optimal control and improved patient safety. In this review, the authors discuss a variety of important issues that must be considered when designing or interpreting studies of the clinical and economic outcomes associated with antimicrobial resistance. Representative literature is reviewed regarding the associations between antimicrobial resistance in specific pathogens and adverse outcomes, including increased mortality, length of hospital stay and cost.

Original languageEnglish (US)
Pages (from-to)751-763
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Volume6
Issue number5
DOIs
StatePublished - Oct 2008

Fingerprint

Economics
Infection
Costs and Cost Analysis
Length of Stay
Mortality
Hospital Costs
Enterococcus
Budgets
Patient Safety
Anti-Infective Agents
Administrative Personnel
Bacterial Infections
Health Care Costs
Bacillus
Staphylococcus aureus
Hospitalization
Anti-Bacterial Agents
Morbidity
Delivery of Health Care
Clinical Studies

Keywords

  • Antimicrobial resistance
  • Economic analysis
  • Healthcare-associated infection
  • Outcome
  • Study design

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

Clinical and economic burden of antimicrobial resistance. / Maragakis, Lisa; Perencevich, Eli N.; Cosgrove, Sara.

In: Expert Review of Anti-Infective Therapy, Vol. 6, No. 5, 10.2008, p. 751-763.

Research output: Contribution to journalArticle

@article{783d790931a54e769325f06109aa7406,
title = "Clinical and economic burden of antimicrobial resistance",
abstract = "Knowledge of the clinical and economic impact of antimicrobial resistance is useful to influence programs and behavior in healthcare facilities, to guide policy makers and funding agencies, to define the prognosis of individual patients and to stimulate interest in developing new antimicrobial agents and therapies. There are a variety of important issues that must be considered when designing or interpreting studies into the clinical and economic outcomes associated with antimicrobial resistance. One of the most misunderstood issues is how to measure cost appropriately. Although imperfect, existing data show that there is an association between antimicrobial resistance in Staphylococcus aureus, enterococci and Gram-negative bacilli and increases in mortality, morbidity, length of hospitalization and cost of healthcare. Patients with infections due to antimicrobial-resistant organisms have higher costs (US$6000-30,000) than do patients with infections due to antimicrobial-susceptible organisms; the difference in cost is even greater when patients infected with antimicrobial-resistant organisms are compared with patients without infection. Given limited budgets, knowledge of the clinical and economic impact of antibiotic-resistant bacterial infections, coupled with the benefits of specific interventions targeted to reduce these infections, will allow for optimal control and improved patient safety. In this review, the authors discuss a variety of important issues that must be considered when designing or interpreting studies of the clinical and economic outcomes associated with antimicrobial resistance. Representative literature is reviewed regarding the associations between antimicrobial resistance in specific pathogens and adverse outcomes, including increased mortality, length of hospital stay and cost.",
keywords = "Antimicrobial resistance, Economic analysis, Healthcare-associated infection, Outcome, Study design",
author = "Lisa Maragakis and Perencevich, {Eli N.} and Sara Cosgrove",
year = "2008",
month = "10",
doi = "10.1586/14787210.6.5.751",
language = "English (US)",
volume = "6",
pages = "751--763",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Clinical and economic burden of antimicrobial resistance

AU - Maragakis, Lisa

AU - Perencevich, Eli N.

AU - Cosgrove, Sara

PY - 2008/10

Y1 - 2008/10

N2 - Knowledge of the clinical and economic impact of antimicrobial resistance is useful to influence programs and behavior in healthcare facilities, to guide policy makers and funding agencies, to define the prognosis of individual patients and to stimulate interest in developing new antimicrobial agents and therapies. There are a variety of important issues that must be considered when designing or interpreting studies into the clinical and economic outcomes associated with antimicrobial resistance. One of the most misunderstood issues is how to measure cost appropriately. Although imperfect, existing data show that there is an association between antimicrobial resistance in Staphylococcus aureus, enterococci and Gram-negative bacilli and increases in mortality, morbidity, length of hospitalization and cost of healthcare. Patients with infections due to antimicrobial-resistant organisms have higher costs (US$6000-30,000) than do patients with infections due to antimicrobial-susceptible organisms; the difference in cost is even greater when patients infected with antimicrobial-resistant organisms are compared with patients without infection. Given limited budgets, knowledge of the clinical and economic impact of antibiotic-resistant bacterial infections, coupled with the benefits of specific interventions targeted to reduce these infections, will allow for optimal control and improved patient safety. In this review, the authors discuss a variety of important issues that must be considered when designing or interpreting studies of the clinical and economic outcomes associated with antimicrobial resistance. Representative literature is reviewed regarding the associations between antimicrobial resistance in specific pathogens and adverse outcomes, including increased mortality, length of hospital stay and cost.

AB - Knowledge of the clinical and economic impact of antimicrobial resistance is useful to influence programs and behavior in healthcare facilities, to guide policy makers and funding agencies, to define the prognosis of individual patients and to stimulate interest in developing new antimicrobial agents and therapies. There are a variety of important issues that must be considered when designing or interpreting studies into the clinical and economic outcomes associated with antimicrobial resistance. One of the most misunderstood issues is how to measure cost appropriately. Although imperfect, existing data show that there is an association between antimicrobial resistance in Staphylococcus aureus, enterococci and Gram-negative bacilli and increases in mortality, morbidity, length of hospitalization and cost of healthcare. Patients with infections due to antimicrobial-resistant organisms have higher costs (US$6000-30,000) than do patients with infections due to antimicrobial-susceptible organisms; the difference in cost is even greater when patients infected with antimicrobial-resistant organisms are compared with patients without infection. Given limited budgets, knowledge of the clinical and economic impact of antibiotic-resistant bacterial infections, coupled with the benefits of specific interventions targeted to reduce these infections, will allow for optimal control and improved patient safety. In this review, the authors discuss a variety of important issues that must be considered when designing or interpreting studies of the clinical and economic outcomes associated with antimicrobial resistance. Representative literature is reviewed regarding the associations between antimicrobial resistance in specific pathogens and adverse outcomes, including increased mortality, length of hospital stay and cost.

KW - Antimicrobial resistance

KW - Economic analysis

KW - Healthcare-associated infection

KW - Outcome

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=55249118181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249118181&partnerID=8YFLogxK

U2 - 10.1586/14787210.6.5.751

DO - 10.1586/14787210.6.5.751

M3 - Article

C2 - 18847410

AN - SCOPUS:55249118181

VL - 6

SP - 751

EP - 763

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 5

ER -